Emerging and Evolving Biomarkers: Molecular Diagnostic and Clinical Perspectives on Microsatellite Instability Testing for Cancer
Molecular Diagnostic and Clinical Perspectives on Microsatellite Instability Testing for Cancer
This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, , audience Q&A, handout, and a post-test. Continuing Education is available for the webinar.
Description:
Microsatellite instability is a genetic pattern observed in cancer that is a surrogate for mismatch repair deficiency. Mismatch repair deficiency can be inherited germline (Lynch syndrome) or somatically acquired in cancer. These have important clinical implications for prevention, screening, and therapeutic treatment of patients who have MSIH+ cancers. This seminar will discuss mismatch repair deficiency, sequencing approaches to assess microsatellite instability, and the clinical significance of finding MSIH status in patients.
Learning Objectives:
- Apply the biological principles that underlie the pathogenicity of microsatellite instability.
- Explain the emergence of next generation sequencing approaches for the molecular diagnostic testing of microsatellite instability.
- Identify the clinical significance
of microsatellite instability.
 |
 |
|---|---|
|
Speaker:
Sameek Roychowdhury, MD, PhD |
Moderator:
Anthony Snow, MD |
Date Recorded: September 22, 2022
Duration: 1 Hour
This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.
- Click the "Enroll" Button
- Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account.
- Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.
Continuing Education Credit Information
CME credit: 1.0CMLE credit: 1.0
Last day to claim credit: December 31, 2024
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This
activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education through the joint providership of American Society
for Clinical Pathology (ASCP) and Association for Molecular Pathology
(AMP). The American Society for Clinical Pathology (ASCP) is accredited
by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the
ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements
for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.